| Brazilian Rare Earths Limited (BRE) ORDINARY FULLY PAID |
Materials |
$220 |
Half Yearly Report and Accounts
|
29 Aug 2024 8:21AM |
$2.660 |
$1.950 |
fallen by
26.69%
|
|
| Atlas Arteria (ALX) FPO STAP US PROHIBITED EXCLUDING QIB/QP |
Industrials |
$7,631 |
Investor Reference Pack to 30 June 2024
|
29 Aug 2024 8:21AM |
$5.090 |
$5.260 |
risen by
3.34%
|
|
ALX - Price-sensitive ASX Announcement
Full Release
Key Points
- Atlas Arteria trades on the Australian Securities Exchange as a stapled security under the code 'ALX'.
- Atlas Arteria's business portfolio includes interests in APRR, ADELAC, Dulles Greenway, Warnow Tunnel, and Chicago Skyway.
- The company provided a detailed analysis of traffic, revenue, and EBITDA for its assets.
- As of 30 June 2024, Atlas Arteria's economic interest in APRR and ADELAC changed to 30.82% and 30.85% respectively following a capital increase at MAF2.
- Atlas Arteria reported on financing and debt metrics for its various assets.
- The report includes maps and detailed descriptions of each toll road asset.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| MedAdvisor Limited (MDR) ORDINARY FULLY PAID |
Health Care |
$54 |
MDR delivers strong revenue growth & inaugural profit
|
29 Aug 2024 8:20AM |
$0.465 |
$0.087 |
fallen by
81.29%
|
|
MDR - Price-sensitive ASX Announcement
Full Release
Key Points
- Achieved 24.6% revenue growth to $122.1 million in FY24.
- Reported inaugural EBITDA profit of $7.0 million.
- Marked first NPAT profit of $0.8 million.
- Significant revenue growth in the US, reaching nearly $100 million.
- Expansion of vaccine and chronic medication programs contributed to growth.
- THRiV platform revenues grew more than sevenfold.
- Transformation 360° initiative to launch in FY25.
- 5-year Strategic Plan targets $250 million revenue and 20%+ EBITDA margin by FY28.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Atlas Arteria (ALX) FPO STAP US PROHIBITED EXCLUDING QIB/QP |
Industrials |
$7,631 |
Half Year Results Investor Presentation to 30 June 2024
|
29 Aug 2024 8:20AM |
$5.090 |
$5.260 |
risen by
3.34%
|
|
ALX - Price-sensitive ASX Announcement
Full Release
Key Points
- Atlas Arteria reported their half-year results for the period ending 30 June 2024.
- The company saw a 3.8% increase in toll revenue and a 0.4% increase in traffic.
- Total EBITDA decreased by 2.9%, primarily due to the new French tax (TEILD).
- The company maintained its distribution guidance for 2024 at 40 cents per security.
- Hugh Wehby was appointed as the incoming CEO and Managing Director, starting late 2024.
- Atlas Arteria achieved significant progress on sustainability targets, including a reduction in Scope 1 and 2 emissions.
- Key financial highlights include a proportionate toll revenue increase of 3.8% and total revenue increase of 4.8%.
- The company has implemented a new reporting methodology for centralized costs starting from H1 2024.
- Capital management initiatives include a €200 million cash reserve release to fund debt amortization.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| E&P Financial Group Limited (EP1) ORDINARY FULLY PAID |
Financials |
- |
Appendix 4E for the year ended 30 June 2024
|
29 Aug 2024 8:20AM |
$0.475 |
$0.515 |
risen by
8.42%
|
|
EP1 - Price-sensitive ASX Announcement
Full Release
Key Points
- Total revenue decreased by 14.7% to $150.48 million.
- Loss for the year after tax attributable to shareholders decreased by 62.6% to $27.679 million.
- Total comprehensive income for the year decreased by 61.3% to $29.434 million.
- No dividends were declared for FY24.
- Net tangible assets per share decreased from $0.24 in 2023 to $0.20 in 2024.
- Basic and diluted loss per share increased from (7.4) cents in 2023 to (12.0) cents in 2024.
- Annual General Meeting scheduled for 12 November 2024.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| MedAdvisor Limited (MDR) ORDINARY FULLY PAID |
Health Care |
$54 |
MDR Appendix 4E and FY24 Annual Report
|
29 Aug 2024 8:20AM |
$0.465 |
$0.087 |
fallen by
81.29%
|
|
MDR - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenues from ordinary activities increased by 24.7% to $122,261,893
- Profit after tax attributable to owners increased by 107.0% to $792,133
- No dividends were declared or paid during the current financial period
- Net tangible assets per ordinary security improved from (3.45) cents to (2.40) cents
- The financial statements received an unmodified audit opinion
- Total revenue for MedAdvisor in FY24 was $122,105,767
- The company reported a profit of $923,583 before income tax and $792,133 after income tax in FY24
- ANZ operations generated segment revenue of $23,702,363, US operations $98,409,442, and UK operations had a minor loss
- Total assets stood at $98,782,647 and total liabilities at $47,199,214 as of June 30, 2024
- Employee benefits expenses totaled $46,422,376, including wages and share-based remuneration
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| QuickFee Limited (QFE) ORDINARY FULLY PAID |
Financials |
$17 |
Notification of cessation of securities - QFE
|
29 Aug 2024 8:19AM |
$0.070 |
$0.051 |
fallen by
27.14%
|
|
| Cettire Limited (CTT) ORDINARY FULLY PAID |
Consumer Discretionary |
$168 |
Rescheduled time of investor webinar for FY24 Results
|
29 Aug 2024 8:19AM |
$1.330 |
$0.440 |
fallen by
66.92%
|
|
| MedAdvisor Limited (MDR) ORDINARY FULLY PAID |
Health Care |
$54 |
MDR Corporate Governance Statement 2024
|
29 Aug 2024 8:18AM |
$0.465 |
$0.087 |
fallen by
81.29%
|
|
| Doctor Care Anywhere Group PLC (DOC) CHESS DEPOSITARY INTERESTS 1:1 |
Health Care |
$37 |
Future Board Change - Ben Kent
|
29 Aug 2024 8:17AM |
$0.070 |
$0.100 |
risen by
42.86%
|
|
| Pioneer Lithium Limited (PLN) ORDINARY FULLY PAID |
Materials |
$4 |
New Drill Targets Identified Additional Ground at VerdeValor
|
29 Aug 2024 8:17AM |
$0.170 |
$0.091 |
fallen by
46.47%
|
|
PLN - Price-sensitive ASX Announcement
Full Release
Key Points
- Pioneer Lithium Limited completed a 300m exploratory auger drilling campaign at the Verde Valor project.
- The campaign confirmed high-grade Rare Earth Elements (REE) with significant clay intercepts including 2,371ppm and 3,139ppm TREO.
- Focusing on delineating high-grade zones, additional geological and structural mapping will be conducted.
- An extra 2,000 hectares has been staked adjacent to high-grade drill holes.
- Auger drilling results revealed significant REE concentrations, particularly in holes TP-AG-009 and TP-AG-005.
- Future drilling campaigns will include auger, RC, and diamond drilling.
- The company's strategy now includes comprehensive geological mapping and structural analysis to enhance understanding of REE mineralisation.
- Preliminary environmental assessments will be initiated to evaluate the feasibility of REE extraction.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Fenix Resources Ltd (FEX) ORDINARY FULLY PAID |
Materials |
$230 |
FY24 Annual Report
|
29 Aug 2024 8:16AM |
$0.295 |
$0.310 |
risen by
5.08%
|
|
| Mesoblast Limited (MSB) ORDINARY FULLY PAID |
Health Care |
$2,179 |
MSB Annual Financial Results and Operational Update
|
29 Aug 2024 8:16AM |
$0.955 |
$1.705 |
risen by
78.53%
|
|
MSB - Price-sensitive ASX Announcement
Full Release
Key Points
- Mesoblast resubmitted its BLA for RYONCIL on July 8, 2024.
- FDA accepted the BLA resubmission within two weeks.
- FDA anticipates a decision on RYONCIL by January 7, 2025.
- Mesoblast commenced enrolling patients in a Phase 3 trial for inflammatory back pain.
- FDA granted Rare Pediatric Disease Designation for Revascor in congenital heart disease.
- Mesoblast recognized a loss of US$88.0 million for FY2024.
- Cash balance at June 30, 2024, was US$63.3 million.
- Revenue for FY2024 was US$5.9 million, down from US$7.1 million in FY2023.
- Research & Development expenses reduced by US$1.8 million in FY2024.
- Manufacturing expenses reduced by US$12.0 million in FY2024.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Silex Systems Limited (SLX) ORDINARY FULLY PAID |
Industrials |
$810 |
Appendix 4G and Corporate Governance Statement
|
29 Aug 2024 8:16AM |
$4.480 |
$3.400 |
fallen by
24.11%
|
|
| Atlas Arteria (ALX) FPO STAP US PROHIBITED EXCLUDING QIB/QP |
Industrials |
$7,631 |
Half Year Results Announcement to 30 June 2024
|
29 Aug 2024 8:16AM |
$5.090 |
$5.260 |
risen by
3.34%
|
|
ALX - Price-sensitive ASX Announcement
Full Release
Key Points
- 2024 distribution guidance of 40.0 cents per security reaffirmed
- Strong growth in proportionate toll revenue (+3.8% compared to H1 2023)
- Net corporate free cash flow up 12.7% compared to H1 2023
- Legal challenge to the new French long-distance transportation infrastructure tax (TEILD) ongoing
- APRR and Eiffage consortium awarded A412 motorway project
- Hugh Wehby appointed as incoming CEO and Managing Director commencing late 2024
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| MedAdvisor Limited (MDR) ORDINARY FULLY PAID |
Health Care |
$54 |
MDR Appendix 4G 2024
|
29 Aug 2024 8:15AM |
$0.465 |
$0.087 |
fallen by
81.29%
|
|
| Bigtincan Holdings Limited (BTH) ORDINARY FULLY PAID |
Information Technology |
$177 |
FY24 Full Year results announcement
|
29 Aug 2024 8:15AM |
$0.120 |
$0.215 |
risen by
79.17%
|
|
BTH - Price-sensitive ASX Announcement
Full Release
Key Points
- Significant revenue opportunities from GenieAI technology expected in FY25
- FY24 EBITDA increased to $11.3 million from $4.9 million in FY23
- Total FY24 revenue was $117.1 million despite regional revenue declines
- Annualized Recurring Revenue (ARR) reached $116 million
- GenieAI technology launched, contributing $1.5 million to ARR
- 2nd largest deal in company history secured with Align Technologies
- A$20.5 million capital raised to support AI investments
- Customer ARR retention rate of 87% achieved
- FY25 projected to see 20%+ EBITDA growth and increased ARR
- Successful strategic partnerships, including Microsoft 365 Copilot integration
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Atlas Arteria (ALX) FPO STAP US PROHIBITED EXCLUDING QIB/QP |
Industrials |
$7,631 |
Appendix 4D and Interim Financial Report
|
29 Aug 2024 8:15AM |
$5.090 |
$5.260 |
risen by
3.34%
|
|
ALX - Price-sensitive ASX Announcement
Full Release
Key Points
- Interim Financial Reports prepared in accordance with Australian Accounting Standards and IAS 34
- Atlas Arteria (ALX) comprises Atlas Arteria International Limited (ATLIX) and Atlas Arteria Limited (ATLAX)
- Net profit after tax attributable to Atlas Arteria stapled securityholders decreased by 16.3% to A$114.2 million
- Revenue and other income increased by 9.6% to A$69.6 million
- Dividends of 20.0 cents per stapled security declared
- Net tangible asset backing per stapled security decreased to A$2.76 from A$2.99
- ALX owns interests in toll roads in France, the US, and Germany
- Toll revenue increased despite decreased traffic numbers due to farmers' strikes in France
- Strategic updates include refinancing debt facilities and releasing trapped cash within the APRR Group
- EBITDA on a proportional basis was €337.7 million for APRR Group in H1 2024
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Aurelia Metals Limited (AMI) ORDINARY FULLY PAID |
Materials |
$499 |
FY24 Full Year Financial Results Presentation
|
29 Aug 2024 8:15AM |
$0.160 |
$0.295 |
risen by
84.38%
|
|
AMI - Price-sensitive ASX Announcement
Full Release
Key Points
- Significant improvement in group margins and cash flow.
- Statutory EBITDA increased by 29%, underlying EBITDA by 45%, and underlying EBITDA margin by 73%.
- Statutory Net Profit After Tax improved by 89%, and underlying Net Profit After Tax turned positive.
- Operational cash flows increased by 119%, and group cash flow improved by 302%.
- FY24 guidance was achieved with strong production results in gold, copper, zinc, and lead.
- FY25 guidance includes expected gold production of 40-50 koz, copper production of 2.5-3.5 kt, zinc production of 14-20 kt, and lead production of 13-19 kt.
- Federation project expected to commence commercial production by July 2025.
- Strong cash balance was maintained with significant liquidity and no drawn debt.
- Continued investment in exploration targeting key extensions at Federation and Nymagee, along with other regional discovery targets.
- Ongoing focus on sustainability and safety performance.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Bigtincan Holdings Limited (BTH) ORDINARY FULLY PAID |
Information Technology |
$177 |
Appendix 4E
|
29 Aug 2024 8:15AM |
$0.120 |
$0.215 |
risen by
79.17%
|
|
BTH - Price-sensitive ASX Announcement
Full Release
Key Points
- Total revenue for FY24 was $117.073 million, a 5% decrease from FY23.
- Loss after tax attributable to members was $14.110 million, a 49% improvement from FY23.
- Net tangible asset per security decreased from (2.99) cents in FY23 to (4.49) cents in FY24.
- Bigtincan Holdings Limited did not declare or recommend any dividends for FY24.
- Basic earnings per share improved from (4.72) cents in FY23 to (2.31) cents in FY24.
- The company focused on customers in its core Ideal Customer Profile (ICP) and achieved a gross margin of 88%.
- Operating expenses decreased by 20% to $111.7 million, with significant restructuring and cost-efficiency measures.
- Adjusted EBITDA nearly doubled from $8.3 million in FY23 to $16.2 million in FY24.
- The acquisition of Modus Engagement Inc. contributed AU$9.5 million to the Group’s revenue.
- The acquisition of imSMART added AU$4.4 million to the Group’s revenue.
- The company’s cash flow from operating activities was $6.170 million despite a net decrease in cash and cash equivalents.
- Bigtincan raised $20.5 million through a capital raising to support its AI technology initiatives.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Halo Technologies Holdings Ltd (HAL) ORDINARY FULLY PAID |
Financials |
$3 |
HALO to issue Convertible Notes to raise up to AUD6.75m
|
29 Aug 2024 8:14AM |
$0.061 |
$0.023 |
fallen by
62.30%
|
|
HAL - Price-sensitive ASX Announcement
Full Release
Key Points
- HALO Technologies Holdings Limited to issue Convertible Notes to raise up to AUD 6.75 million
- Funds will be used for continued growth, global expansion, innovation in service offerings, and distribution channel growth
- Convertible Notes will have a term of 60 months with interest of 12% p.a., compounded monthly and payable quarterly in arrears
- HALO grew its Funds Under Management by 88.6% to $421.3 million and operating revenue by 44.3% to $9.77 million in the 12 months to 30 June 2024
- The Notes will have a conversion date when VWAP of HALO shares for preceding 90 days is not less than $0.41
- Conversion rate set at Principal Amount divided by $0.35
- HALO has established a subsidiary, HALO Invest, in the UK to handle financial products and services
- HALO Invest has completed initial trading transactions in the UK
- The offer for Convertible Notes opens on 29 August 2024 and will close 6 months from the date of opening unless extended by the Board
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Aurelia Metals Limited (AMI) ORDINARY FULLY PAID |
Materials |
$499 |
2024 Group Mineral Resource and Ore Reserve Statement
|
29 Aug 2024 8:14AM |
$0.160 |
$0.295 |
risen by
84.38%
|
|
AMI - Price-sensitive ASX Announcement
Full Release
Key Points
- Group Mineral Resource Estimate of 26Mt with key changes including the addition of the maiden Queen Bee estimate and mining depletion adjustments.
- Group Ore Reserve Estimate of 4.7Mt with key changes including mining depletion across all operations.
- Exploration drill results support the maiden Mineral Resource Estimate for Queen Bee of 560kt @ 2.2% Cu.
- Dargues Mine has been removed from the 2024 Mineral Resource and Ore Reserve Estimate as the mining operation has ceased.
- Aurelia Metals produced 65,315 ounces of gold at a Group All-In Sustaining Cost of A$2,035 per ounce in FY24.
- Peak continues to transition to copper-dominant mining with copper ore now 87% of the Ore Reserve tonnage.
- Federation Mine’s Ore Reserve tonnage remained at 2.4Mt.
- Nymagee MRE tonnage increased by 16% to 2.3Mt following a successful surface drilling campaign.
- Queen Bee added as a maiden Mineral Resource following a successful drilling campaign.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Aurelia Metals Limited (AMI) ORDINARY FULLY PAID |
Materials |
$499 |
FY24 Financial Results and FY25 Guidance
|
29 Aug 2024 8:14AM |
$0.160 |
$0.295 |
risen by
84.38%
|
|
AMI - Price-sensitive ASX Announcement
Full Release
Key Points
- FY24 gold production was 65,315 ounces with an All-In Sustaining Cost (AISC) of $2,035 per ounce.
- Peak ore mined increased by 17% to 580kt in FY24.
- Underlying EBITDA increased by 45% to $81.0 million.
- Underlying net profit after tax improved by 102% to $0.6 million.
- Statutory net loss after tax improved by 89% to $5.7 million.
- Cash flows from operating activities increased by 119% to $100.6 million.
- Federation project to commence stope ore production in Q1 FY25.
- Group Ore Reserves are 4.7Mt and Group Mineral Resources are 26Mt.
- Significant cash balance of $116.5 million as of 30 June 2024.
- FY25 guidance includes gold production of 40-50koz, copper production of 2.5-3.5kt, zinc production of 14-20kt, and lead production of 13-19kt.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Aurelia Metals Limited (AMI) ORDINARY FULLY PAID |
Materials |
$499 |
2024 Group Production Target Statement
|
29 Aug 2024 8:14AM |
$0.160 |
$0.295 |
risen by
84.38%
|
|
AMI - Price-sensitive ASX Announcement
Full Release
Key Points
- Approximately 96% of Group Production Target tonnage is from Peak copper and Federation zinc-lead deposits
- Group Production Target tonnage is 8.2Mt at A$270/t NSR
- Dargues Mine has been removed from the 2024 Production Target
- Peak Mine is transitioning to a copper-dominant mining operation
- Peak Mine Production Target tonnage decreased by 11% to 4.2Mt due to mining depletion
- Federation Mine Production Target tonnage is unchanged at 4.0Mt
- Ore drive development at Federation mine has commenced with first stope ore production expected in Q1 FY25
- The Production Target is derived from Measured, Indicated, and Inferred Mineral Resource classifications
- The Group Production Target includes 57% Ore Reserve Estimate and 26% Inferred Mineral Resource
- Material assumptions for Production Targets follow ASX Listing Rules Chapter 5
- The Federation Mine Production Target is supported by findings from the Feasibility Study and associated updates
- Environmental monitoring requirements are in place for the Federation Project
- Various power options are being investigated for the Federation Project
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Mesoblast Limited (MSB) ORDINARY FULLY PAID |
Health Care |
$2,179 |
Annual Financial Results Presentation
|
29 Aug 2024 8:13AM |
$0.955 |
$1.705 |
risen by
78.53%
|
|
MSB - Price-sensitive ASX Announcement
Full Release
Key Points
- Mesoblast aims to bring innovative off-the-shelf allogeneic cellular medicines to market for treating serious inflammatory illnesses.
- RYONCIL has been resubmitted to the FDA for approval for steroid-refractory acute graft versus host disease (SR-aGVHD) in pediatric patients.
- Mesoblast strategy involves gaining initial pediatric approval for RYONCIL followed by label extension in adult patients.
- The company has started pre-launch activities and hiring for commercial roles in anticipation of FDA approval for RYONCIL.
- RYONCIL has shown a 67% survival rate at 100 days in SR-aGVHD patients who failed other treatments like ruxolitinib.
- The company plans to start Phase 3 trials of RYONCIL in adults and adolescents with SR-aGVHD post pediatric approval.
- REVASCOR has been granted Rare Pediatric Disease Designation and Orphan Drug Designation by the FDA for treating hypoplastic left heart syndrome (HLHS).
- Mesoblast is working towards accelerated approval of REVASCOR in adults with heart failure with reduced ejection fraction (HFrEF).
- Rexlemestrocel-L is being developed for chronic low back pain due to degenerative disc disease (CLBP) and has shown more than three years of pain reduction in trials.
- The company has reduced manufacturing expenses and headcount costs to manage financial performance.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Goals & planningInvesting goal hubsSaving to build wealth
Saving for happy retirement 
Call 1300 880 160
Start a chat
Schedule a call
